BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms

As Amgen advances its bid to join the first wave of biosimilars to Bristol Myer Squibb and Ono’s oncology mega-blockbuster Opdivo, the originator drug’s partners are not taking the challenge lying down.